<DOC>
	<DOCNO>NCT01852045</DOCNO>
	<brief_summary>This study evaluate safety efficacy onabotulinumtoxinA treatment urinary incontinence due neurogenic detrusor overactivity pediatric patient age 5 17 year .</brief_summary>
	<brief_title>Study OnabotulinumtoxinA Urinary Incontinence Due Neurogenic Detrusor Overactivity Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Urinary incontinence due neurogenic detrusor overactivity Regularly use clean intermittent catheterization empty bladder Surgery spinal cord within 6 month Diagnosis cerebral palsy Current plan use baclofen pump Current plan use electrostimulation/neuromodulation device urinary incontinence Use indwelling catheter urinary incontinence instead use clean intermittent catheterization empty bladder Previous current use botulinum toxin therapy serotype urological condition , treatment botulinum toxin serotype within 3 month condition use Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>